EU-supported international research project aims to improve obesity treatment an ... Read more
Novo Nordisk launches new social responsibility strategy to defeat diabetes ... Read more
Novo Nordisk A/S – Share repurchase programme ... Read more
Novo Nordisk A/S – Share repurchase programme ... Read more
Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placeb ... Read more
Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more
If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.
27 May - At a time of acute global health need, Novo Nordisk today announced the launch of a new social responsibility strategy: ‘Defeat Diabetes’. The strategy strengthens Novo Nordisk’s commitment and introduces new long-term ambitions to provide access to affordable diabetes care to vulnerable patients in every country and to ensure that no child should die from type 1 diabetes.
“Our purpose to defeat diabetes is necessary now more than ever as diabetes continues to rise, and at a time when the world is suffering from the most devastating pandemic in recent times,” said Lars Fruergaard Jørgensen, CEO of Novo Nordisk. “In addition to innovative medicine, we are committed to help societies defeat diabetes by accelerating prevention to halt the rise of the disease and providing access to affordable care to vulnerable patients in every country. Vulnerability has many faces, and diabetes hits the hardest in vulnerable communities. I am proud that we are stepping up our efforts and working in partnerships to tackle the diabetes crisis at a time of profound need.”
Read more about Novo Nordisk's Defeat Diabetes strategy
Bagsværd 13 May - Novo Nordisk today announced headline results from STEP 4, the first completed phase 3a trial in the STEP programme. STEP 4 is a randomised, double-blind, multicentre, placebo-controlled, withdrawal trial exploring sustained weight management with semaglutide vs placebo. The 68-week trial investigated the effect of once-weekly subcutaneous (sc) semaglutide 2.4 mg on body weight in 902 people with obesity or overweight with comorbidities. After the 20-week run-in period, the 803 people reaching the target dose of semaglutide 2.4 mg had reduced their mean body weight from 107.2 kg to 96.1 kg and were randomised to continued treatment with either once-weekly sc semaglutide 2.4 mg or placebo for 48 weeks.
Estimated sales growth adjusted for COVID-19-related stocking around 7% at CER
6 May 2020 - Lars Fruergaard Jørgensen,
president and CEO comments on the financial results for the first
three months of 2020: "Societies are severely impacted by the
COVID-19 outbreak, and during the pandemic our key priorities are to
safeguard our employees, continue the supply of our
life-saving medicines and use our expertise, resources and global
reach to help societies around the world during the pandemic.
COVID-19-related stocking impacted our results; however, we are
satisfied with the underlying commercial performance as well as the
progression of our pipeline with the approval of Rybelsus
® in the EU and the encouraging
phase 2 data for semaglutide in NASH."
Read all the details in the announcement
31 March - During the global coronavirus outbreak, Novo Nordisk’s key priority is to safeguard the continued supply of our lifesaving medicines to patients.
The situation is continually evolving, but currently we are not experiencing any supply constraints. We are well prepared for situations like this and have an inventory policy that serves long-term supply. This is important since our medicines are needed every day by patients all over the world.
Updates on Novo Nordisk's latest contributions and initiatives
20 November - Novo Nordisk and UNICEF have announced a new partnership to help prevent childhood overweight and obesity worldwide with an initial focus on interventions in Latin America and the Caribbean.
Under this partnership, the United Nations children’s agency and the global healthcare company will combine efforts to enhance knowledge and awareness on how to prevent overweight and obesity and address their root causes. The partnership will initially cover a period of three years.
“There is no doubt that childhood overweight and obesity is a public health crisis that requires immediate attention. Childhood overweight and obesity is more than an individual choice, this is everybody’s business. Together with UNICEF, we hope to help millions of children lead healthy lives and at the same time ease the burden of obesity to society,” said Novo Nordisk President and CEO Lars Fruergaard Jørgensen.
Read the full press release on the partnership
What if medicines injected by millions could be delivered in tablets?
After almost 100 years of delivering injectable therapies, Novo
Nordisk’s R&D team is finding answers to this enduring question.
Chief Science Officer Mads Krogsgaard Thomsen is leading the way and
he reflects on the magnitude of the scientific challenge and the
progress made in his laboratories.
Novo Nordisk intends to achieve the target to use only renewable electricity in
its global production facilities by 2020. The announcement on 30
April followed a new investment in a 672-acre solar panel
installation, roughly the size of 500 football fields, in North
Carolina, US, which will provide power to Novo Nordisk’s entire US
operations from early 2020. Novo Nordisk is the first pharmaceutical
company in
RE100
to use only renewable electricity
in production. RE100 is a collaborative, global initiative of
businesses committed to using 100% renewable electricity.
Read more about Circular
for Zero and download
the full press release on the environmental ambitions
The International Committee of the Red Cross (ICRC), the Danish Red
Cross (DRC) and Novo Nordisk have partnered to tackle the growing
issue of chronic diseases that affect millions of people living in
humanitarian crises around the world. Focus will be on ensuring
efficient supply of low-cost human insulin in vials to Red Cross
globally; support for ICRC’s and DRC’s health programmes; 2-3 projects
to provide care to people with hypertension and diabetes in
humanitarian crises to be conducted within three years.
Read CEO Lars Fruergaard's reflections and more about the partnership
6 May - first quarter
6 August - first 6 months
30 October - first 9 months
When Pâris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years.
